Core Viewpoint - Niagen Bioscience, Inc. (NASDAQ: NAGE) is set to hold a conference call on March 4, 2026, to discuss its financial results for Q4 and fiscal year 2025, which ended on December 31, 2025 [1]. Financial Results Announcement - The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call [1].

Core Viewpoint - Niagen Bioscience, Inc. has acquired a comprehensive portfolio of patents related to nicotinamide riboside (NR) from Queen's University Belfast, enhancing its leadership in NAD+ precursor intellectual property [1] Group 1: Company Developments - The acquisition strengthens Niagen's long-standing ownership position in the NAD+ precursor market [1] - The focus of the company is on the science of healthy aging, positioning it as a global authority in NAD+ [1] Group 2: Industry Implications - The acquisition of these patents may lead to increased innovation and product development in the field of healthy aging and NAD+ research [1] - This move could potentially enhance the competitive landscape within the biotech industry, particularly in the area of aging-related health solutions [1]